Pixabay
Pixabay
The development process for a COVID-19 treatment therapy is underway at a North Carolina medical facility.
While Spain-based multinational pharmaceutical and chemical manufacturer Grifols, S.A., is working with federal health agencies on the potential treatment at its facility in Clayton, it is unknown if many would be able to afford it.
Grifols, the U.S. Food and Drug Administration, U.S. Biomedical Advanced Research Development Authority and other entities are conducting plasma fractionation, the process of separating various components of blood plasma, in an effort to come up with a sterile solution called immune globulin. Should the solution prove effective, it will be administered to people stricken with the coronavirus.
As the largest plasma donor center network in the U.S., Grifols has started the process of identifying, screening and selecting from cities hardest hit by the disease. The federal government is helping with the process.
Alerts Sign-up